MoonLake Immunotherapeutics (ticker: MLTX) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of MLTX's SEC filings surfaces 2 active risk signals, including 1 auditor-change signal, and 1 late-filing signal. MLTX reported no tagged revenue in revenue and -$69.71M for the period ending 2026-03-31, with operating cash flow of -$66.29M. Cash and equivalents stood at $298.49M (up 9.9% year-over-year). Total assets of $400.37M exceed total liabilities of $146.35M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
MLTX SEC Filings
Full cached SEC EDGAR filing history for MLTX, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.